These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 11079044)

  • 1. Clinical pharmacology of inflammatory bowel disease therapies.
    Sandborn WJ; Faubion WA
    Curr Gastroenterol Rep; 2000 Dec; 2(6):440-5. PubMed ID: 11079044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
    Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
    Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
    Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
    Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
    Sedano Muñoz R; Quera Pino R; Ibáñez Lazo P; Figueroa Corona C; Flores Pérez L
    Gastroenterol Hepatol; 2019 May; 42(5):339-347. PubMed ID: 30954317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose methotrexate in inflammatory bowel disease: current status and future directions.
    Schröder O; Stein J
    Am J Gastroenterol; 2003 Mar; 98(3):530-7. PubMed ID: 12650783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with the use of low-dose methotrexate for inflammatory bowel disease.
    Soon SY; Ansari A; Yaneza M; Raoof S; Hirst J; Sanderson JD
    Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):921-6. PubMed ID: 15316419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy modifies HLA-G secretion differently in Crohn's disease and ulcerative colitis patients.
    Zelante A; Borgoni R; Galuppi C; Cifalà V; Melchiorri L; Gullini S; Baricordi O; Rizzo R
    Inflamm Bowel Dis; 2011 Aug; 17(8):E94-5. PubMed ID: 21604331
    [No Abstract]   [Full Text] [Related]  

  • 11. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
    Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
    Lee MN; Kang B; Choi SY; Kim MJ; Woo SY; Kim JW; Choe YH; Lee SY
    Inflamm Bowel Dis; 2015 Dec; 21(12):2897-908. PubMed ID: 26332308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical management of patients with difficult-to-treat inflammatory bowel disease.
    van Hogezand RA
    Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics in inflammatory bowel disease.
    Pierik M; Rutgeerts P; Vlietinck R; Vermeire S
    World J Gastroenterol; 2006 Jun; 12(23):3657-67. PubMed ID: 16773681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current medical therapy for inflammatory bowel disease.
    Bonner GF
    South Med J; 1996 Jun; 89(6):556-66. PubMed ID: 8638193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory bowel disease.
    Podolsky DK
    N Engl J Med; 2002 Aug; 347(6):417-29. PubMed ID: 12167685
    [No Abstract]   [Full Text] [Related]  

  • 17. Newer treatments for inflammatory bowel disease.
    Stotland BR; Lichtenstein GR
    Prim Care; 1996 Sep; 23(3):577-608. PubMed ID: 8888346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Classical medications in the treatment of inflammatory bowel diseases].
    Duvnjak M; Bilić A; Barsić N; Tomasić V; Stojsavljević S
    Acta Med Croatica; 2013 Apr; 67(2):111-24. PubMed ID: 24471294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores].
    Geboes K; Desreumaux P; Jouret A; Ectors N; Rutgeerts P; Colombel JF
    Gastroenterol Clin Biol; 1999 Oct; 23(10):1062-73. PubMed ID: 10592879
    [No Abstract]   [Full Text] [Related]  

  • 20. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?
    Chande N; Marshall JK; Seow CH; Sandborn WJ; Parker CE; Nelson S; Feagan BG
    Inflamm Bowel Dis; 2015 Dec; 21(12):2948-57. PubMed ID: 26540276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.